HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haxhinasto, S. A. Articles by Bishop, G. A. Search for Related Content PubMed PubMed Citation Articles by Haxhinasto, S. A. Articles by Bishop, G. A.

A Novel Interaction between Protein Kinase D and TNF Receptor-Associated Factor Molecules Regulates B Cell Receptor-CD40 Synergy¹

Sokol A. Haxhinasto^* and Gail A. Bishop^2,*,,

^* Interdisciplinary Program in Immunology and Departments of Microbiology and Internal Medicine, University of Iowa, Iowa City, IA 52242; and Veterans Administration Medical Center, Iowa City, IA 52242

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Signaling by Ag to the B cell Ag receptor (BCR) is enhanced by several cooperating signals, including several provided by B-T cell interactions. One of these, CD40, provides critical signals for B cell differentiation, isotype switching, and B cell memory. The molecular mechanisms by which BCR and CD40 signals synergize are not well understood. Although the BCR and CD40 share certain signaling pathways, we hypothesized that unique signals provided by each could provide mutual enhancement of their signaling pathways. The BCR, but not CD40, activates protein kinase D (PKD), while CD40, but not the BCR, employs the TNFR-associated factor (TRAF) adapter proteins in signaling. In this study, we show that genetic or pharmacologic inhibition of BCR-mediated PKD activation in B lymphocytes abrogated the synergy between the CD40 and the BCR, as measured by activation of Ig and cytokine secretion. Interestingly, the role of PKD was dependent upon the association of CD40 with TRAF2, and was inhibited by the binding of TRAF3, revealing a novel functional link between these two classes of signaling molecules.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Signals delivered by the B cell Ag receptor (BCR)³ play a critical role during B lymphocyte development and activation (1, 2). BCR signaling is mediated directly by protein tyrosine kinases of the Src, Syk/Zap-70, and Tec families, as well as protein tyrosine phosphatases, such as CD45 (3). Activation of protein tyrosine kinases triggers a cascade of secondary signals, resulting in activation of several intracellular effector signaling molecules, including members of the protein kinase C (PKC) family of serine-threonine kinases (4). BCR-mediated PKC activation influences diverse aspects of BCR signaling, including activation of transcription factors, such as NF-B (5) and CREB (6).

The PKC family can be divided into three subfamilies, depending on the second messengers required. The conventional PKCs (PKC-, , _II, ) use both diacylglycerol (DAG) and Ca²⁺ for their activation, relying primarily on the phospholipase C- (PLC-) pathway. The activation of novel PKCs (PKC-, , , ) is DAG dependent and Ca²⁺ independent. The atypical PKCs (PKC-, /) are activated by neither DAG nor Ca²⁺ and have been shown to be downstream of phosphatidylinositol 3 kinase (7). More recently, the protein kinase D (PKD) family has been described, with PKC-µ/PKD as its main member (8). B lymphocytes express PKC-, , , , , , , and µ isoforms, and BCR engagement has been shown to induce their activation (9, 10, 11).

PKD is a downstream target of second messengers, primarily DAG, and represents a novel family of serine/threonine kinases. Structurally, PKD consists of an N-terminal region rich in alanines and prolines, two cysteine-rich zinc-finger regions, followed by a pleckstrin homology (PH) domain and a protein Ser/Thr kinase catalytic domain (reviewed in Ref. 8). Different from the other PKCs, PKD does not possess an autoinhibitory pseudosubstrate sequence, and is not inhibited by PKC inhibitors, including Gö6983 (12). PKD is activated upon phosphorylation of two serines in the activation loop (Ser^744/748) upon various stimuli, including BCR engagement (13, 14, 15).

Extensive work has been done to determine the signaling pathways that activate PKD. These studies showed that PKD is activated by multiple signals (review in Ref. 8), including BCR engagement in B lymphocytes (10, 16, 17). To date, the contribution of PKD in BCR signaling is not clear. It has been suggested that PKD negatively regulates BCR signaling by phosphorylating Syk and reducing its ability to phosphorylate PLC- (10).

Although BCR engagement by Ag is necessary for B lymphocyte activation, it is not sufficient for full activation; this requires contact-mediated interaction with Ag-specific Th cells and engagement of additional signaling receptors, including CD40 (18). CD40 is a member of the TNFR family that plays a crucial role in B cell proliferation, differentiation, isotype switching, up-regulation of surface molecules, development of germinal centers, and immunological memory. The critical role of CD40 and its interaction with its ligand, CD154, are evident in humans with X-linked hyperIgM syndrome (19, 20, 21), as well as in mice lacking either CD40 (22, 23) or its ligand CD154 (24). The CD40 cytoplasmic tail does not contain any tyrosine residues to serve as docking sites for tyrosine-dependent downstream signaling molecules. However, CD40 relies on adapter molecules, such as TNFR-associated factors (TRAFs), in transmission of its signals (25). CD40 engagement in B lymphocytes leads to CD40 association with several TRAFs (26), and activation of various kinases and transcription factors (27, 28).

It is evident from several studies that coengagement of the BCR and CD40 has synergistic effects on B lymphocyte function, including B cell proliferation and production of IgM, TNF-, and IL-6 (29, 30, 31, 32, 33). However, the molecular mechanisms responsible for this synergy are not completely understood. Despite the ability to activate some of the same kinases and transcription factors, the BCR and CD40 are also able to activate distinct signaling molecules, which may contribute to the synergy between these receptors. Recently, we showed that the BCR is able to enhance the response of B lymphocytes to CD40 in a TRAF2-dependent manner. Mutant CD40 molecules that bind TRAF3 in the absence of TRAF2 are not able to synergize, implying a positive role for TRAF2 and a negative or neutral role for TRAF3 in the BCR/CD40 cross talk (30). However, it is still unclear what signaling molecule(s) downstream of BCR engagement is important for the enhancement of the CD40 response. We hypothesized that the BCR is able to augment the CD40 response by activating unique signaling molecule(s) that CD40 is unable to activate. Previous studies have clearly shown that the BCR activates several isoforms of PKC, while CD40 signaling is PKC independent (34, 35, 36). We thus investigated the role of PKC in the molecular interactions between BCR and CD40. We found that activation of the PKC isoform PKD was necessary for the synergy between BCR and CD40. Unexpectedly, the action of PKD was TRAF2 dependent, and was inhibited by TRAF3, demonstrating a critical novel functional link between PKD and TRAF molecules in bridging the signaling pathways of the BCR and CD40 in B lymphocytes.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cells

The mouse B cell line CH12.LX expresses surface IgM specific for phosphatidylcholine, an Ag found on the surface of SRBC (37), and has been well characterized (38). The CH12.LacR subclone used for the inducible expression of stably transfected molecules has been previously described (39). Subclones of CH12.LX lacking either TRAF2 or TRAF3 were produced by homologous recombination-based gene targeting, and are described in detail elsewhere⁴ (58). All B cells were cultured in RPMI 1640 supplemented with 10% FCS, 10 µM 2-ME, and antibiotics (B cell medium-10/B cell medium). Spodoptera frugiperda (Sf9) cells infected with wild-type (WT) or a recombinant baculovirus expressing mCD154 were prepared as previously described (29). Mouse C57BL/6 splenic B cells were prepared as described (29). SRBC were obtained from Elmira Biologicals (Iowa City, IA) and were used in cultures as a source of Ag at a final concentration of 0.1%.

DNA constructs and transfection

The human CD40 (hCD40) constructs used have been previously described (39, 40). PKD cDNA constructs (WT, and mutants KD (kinase dead) and EE (constitutively active)) were a generous gift from V. Malhotra (University of California San Diego, La Jolla, CA). All PKD constructs were subcloned into the inducible expression vector pOPRSVI.mcs1 (39). PCR amplification and subcloning by overlap extension were used for generation of PKD-PH domain deleted (PHD) mutants (41). Stable transfections of CH12.LX were generated for all the hCD40 and PKD constructs, and were performed by electroporation, as described (40).

Abs and chemicals

Isopropyl-B-D-thiogalactopyranoside (IPTG) was purchased from Amresco (Solon, OH) and was used at a final concentration of 100 µM. Mouse IgG1 isotype control mAb (MOPC-21) was purchased from Sigma-Aldrich (St. Louis, MO). Rabbit anti-PKD and rabbit anti-phospho-744/748 PKD were purchased from Cell Signaling (Beverly, MA). Goat anti-rabbit HRP was purchased from Bio-Rad Laboratories (Hercules, CA). The following Abs were produced in our laboratory by hybridomas purchased from the American Type Culture Collection (ATCC, Manassas, VA) or were gifts from the indicated individuals: anti-hCD40 (G28-5, mIgG1) from ATCC, anti-mouse CD40 (1C10, rat IgG2a) from F. Lund (Trudeau Institute, Saranac Lake, NY), and anti-mouse IgE (EM95.3, isotype control, rat IgG2a) from T. Waldschmidt (University of Iowa, Iowa City, IA). Goat anti-mouse µ-chain-specific F(ab')₂ was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Goat anti-mouse () was purchased from Southern Biotechnology (Birmingham, AL). Mouse anti-Flag (M2) Ab was purchased from Sigma-Aldrich. All chemical inhibitors, staurosporine, H-7, Gö6976, and Gö6983 were purchased from Calbiochem (San Diego, CA).

Assays for B cell function

IgM-secreting cells per million recovered viable cells were measured by direct plaque-forming cell assay, as previously described (42). Inducible TRAF expression was initiated by addition of IPTG to cultures 18 h before addition of stimuli. All stimulations proceeded for a total of 72 h, including the time of IPTG incubation. In all experiments, control stimulation included Ag and isotype controls for respective Abs. Cytokine ELISAs were performed, as described previously (30). For proliferation studies, 1 x 10⁵ cells were stimulated with 1 µg/ml of anti- and/or anti-CD40 Abs for 72 h. Five to six hours before harvesting, 1 µCi of [³H]thymidine was added to each well, and incorporation was determined by liquid scintillation counter. When using chemical inhibitors, cells were pretreated for 30 min before the stimuli were added. Concentrations of inhibitors that showed no detectable toxicity to our cells, as measured by trypan blue exclusion, were chosen for longer assays.

Western blotting and immunoprecipitation

CH12.LX cells (5–10 x 10⁶) were stimulated for 30 min with 10 µg/ml of anti-mouse µ-chain-specific F(ab')₂, 100 ng/ml of PMA, or mCD154-expressing cells (1 mCD154-expressing cell:4 B cells). Total cell lysates were subjected to SDS-PAGE and electroblotted onto nitrocellulose paper, and Western blotting was performed. To detect the PKD protein upon IPTG induction, cells were lysed in 1% Nonidet P-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris (pH 7.5), 0.02% NaN₃, and protease and phosphatase inhibitors) for 30 min. The supernatants were incubated with protein G beads preconjugated with anti-Flag Ab. Immunoprecipitated proteins were separated by SDS-PAGE, and Western blotting was performed.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Pharmacologic inhibition of PKD activity abrogated BCR-CD40 synergy

Engagement of CD40 on normal B cells or on the B cell line CH12.LX results in production of IgM, TNF-, and IL-6, and BCR signals synergize with these CD40 functions (32, 43, 44, 45). We hypothesized that the BCR enhances the CD40 response by activating distinct signaling molecules unique to the BCR pathway. To test the role of serine/threonine kinases in the synergy, two broad-spectrum serine/threonine kinase inhibitors, staurosporine and H-7, were examined. Interestingly, synergy between the BCR and CD40 was abrogated upon treatment of cells with these kinase inhibitors, while the CD40 response was not affected (Fig. 1). BCR signaling alone does not stimulate IgM secretion (40). A candidate serine/threonine kinase, activated by the BCR, but not CD40, is PKC (34, 35, 36). BCR engagement leads to activation of several isoforms of PKC (9, 10, 11). To test the role of PKCs in the synergy between BCR and CD40, cells were treated with two highly specific staurosporine-derived PKC inhibitors, Gö6976 and Gö6983 (12, 46, 47), and the ability of the BCR to enhance the CD40 response was examined. TNF- is produced within 3 h of CD40 stimulation, so in the experiments shown in Fig. 2C, a higher concentration of inhibitors could be used. However, higher concentrations show toxicity during the longer time periods (48–72 h) required for IL-6 or IgM production, so doses above 200 nM were not used in these experiments. As in Fig. 1, the CD40 response was not affected by treatment of cells with PKC inhibitors (Fig. 2). Interestingly, Gö6976 abrogated the synergy between BCR and CD40 in splenic B cell proliferation (Fig. 2A), IgM secretion (Fig. 2B), and TNF- and IL-6 production (Fig. 2, C and D), while Gö6983 did not affect synergy. Both inhibitors have been reported to inhibit conventional PKC isoforms such as PKC and PKC, but only Gö6976 has been shown to additionally inhibit PKD (12, 47). We examined the effect of Gö6976 and Gö6983 on PKD activation in CH12.LX B cells and splenocytes. BCR engagement has been shown to activate PKD in freshly isolated B lymphocytes (10). Fig. 3 shows that BCR engagement also led to PKD activation in CH12.LX B cells (Fig. 3A) and splenocytes (Fig. 3B), but stimulation of CD40 (mCD154) did not. Gö6976, but not Gö6983, inhibited PKD activation in CH12.LX cells (Fig. 3A) and splenocytes (Fig. 3B), indicating that the effects of these drugs on B cell effector functions (Fig. 2) are most likely due to their specific effects on PKD activation. Previous studies have suggested that PKD is activated in a PKC-dependent manner (17, 48); however, these authors used different PKC inhibitors than the drugs we used, so the results cannot be compared directly. In addition, previous studies (47) have indicated a differential effect of Gö6976 and Gö6983 on PKC vs PKD. It is possible that the inhibition of classical PKC by Gö6983 is not complete, and therefore some PKD activation still occurs in the presence of Gö6983, or that other PKC-independent pathways exist to activate PKD in B lymphocytes. Regardless of what is upstream of PKD, our data strongly suggested that PKD is critical for the synergy between BCR and CD40.

View larger version (18K): [in this window] [in a new window]   FIGURE 1. Effects of serine/threonine kinase inhibitors on BCR/CD40 synergy. CH12.LX cells were cultured with the indicated stimuli (2 µg/ml 1C10 anti-CD40 mAb and 0.1% SRBC as Ag), and IgM secretion was measured after 72 h of culture, as described in Materials and Methods. Serine/Threonine kinase inhibitors were included in cultures at final concentrations equal to their Ki for PKC of 6 µM for H7 and 700 pM for staurosporine.

View larger version (27K): [in this window] [in a new window]   FIGURE 2. BCR/CD40 synergy was abrogated by Gö6976, but not Gö6983. Cells were stimulated as indicated in the presence or absence of the pharmacologic inhibitors. A, Splenic B cell proliferation was measured after 72 h by the uptake of [3H]thymidine, as in Materials and Methods. Inhibitors were included in cultures at a final concentration of 100 nM. B, IgM secretion was measured as in Fig. 1. Inhibitors were included in cultures at a final concentration of 100 nM. C, TNF- secretion was measured after 3 h of culture with the indicated stimuli, using ELISA, as in Materials and Methods. B cells were pretreated for 30 min with the indicated concentrations of inhibitors before the stimuli were added. Sf9 insect cells are used as a control for insect cells infected with mCD154-expressing recombinant baculovirus, as described in Materials and Methods. DMSO controls for the diluent used to make a concentrated stock of the inhibitors. D, IL-6 secretion was measured after 48 h of culture, by ELISA, as described in Materials and Methods. Inhibitors were included in cultures at the indicated final concentrations. Results presented in all panels are mean ± SD of replicate cultures and are representative of at least three similar experiments.

View larger version (55K): [in this window] [in a new window]   FIGURE 3. BCR-induced PKD activation is inhibited by Gö6976, but not Gö6983. A, CH12.LX (5–10 x 106) B cells or splenocytes (B) were stimulated for 15–30 min with 10 µg/ml of goat anti-mouse µ-chain-specific F(ab')2, fragments of IgG, 100 ng/ml of PMA, or mCD154-expressing Sf9 cells (1 mCD154-expressing cell:4 B cells). Cells were incubated for 30 min with the indicated inhibitors before stimulation. Total cell lysates were subjected to SDS-PAGE and electroblotted onto nitrocellulose paper, and Western blotting was performed. A representative experiment of at least two similar experiments is shown.

Chemical inhibitors, while providing important clues, have limitations due to potentially unknown, nonspecific effects. To more directly address the role of PKD in the cross talk between BCR and CD40, we used an IPTG-inducible system (described in Ref. 39) to express various PKD-expressing constructs in CH12.LX B cells. This allowed controlled expression of the PKD. Previous studies have shown that substitution of lysine 618 with asparagine (K618N) in PKD’s catalytic domain prevents ATP from binding and creates a catalytically inactive PKD that serves as a dominant-negative molecule (15, 48, 49). Replacement of serines at positions 744 and 748 with alanines (AA) also leads to inactivation of PKD, while replacement of these residues with glutamic acid leads to a constitutively active PKD (EE) (13). We combined K618N and the SS744/748AA mutations to generate the inactive (KD) PKD.

We inducibly expressed WT, the PKD-EE, and PKD-KD (Fig. 4A) in CH12.LacR cells. The constructs were Flag tagged at the N terminus to differentiate the exogenous, inducible PKD from the endogenous enzyme. Expression of the recombinant proteins was confirmed by intracellular staining and flow cytometry (data not shown) as well as Western blot analyses (Fig. 4B). The effects of expression of WT (Fig. 4C) and mutant (Fig. 4D) PKD molecules on CD40-mediated IgM production were tested. WT PKD did not affect the CD40 response alone and slightly increased the magnitude of synergy between BCR and CD40. Expression of PKD-KD (Fig. 4D) abrogated the synergy between BCR and CD40, without affecting the CD40 response, demonstrating that BCR-induced PKD activation is necessary for the synergy between BCR and CD40. This demonstrates that functional PKD is specifically required for BCR-CD40 synergy.

View larger version (27K): [in this window] [in a new window]   FIGURE 4. Effects of expression of PKD mutants on BCR-CD40 synergy. A, Schematic representation of PKD mutants used. Mutated residues in the catalytic domain are indicated. B, Expression of the PKD constructs. CH12.LacR cells stably transfected with the various PKD constructs were cultured in 100 µM IPTG overnight to induce expression of the recombinant proteins. Cells were lysed, and immunoprecipitation was performed, as described in Materials and Methods. Immunoprecipitated proteins were separated by SDS-PAGE, and Western blotting was performed with anti-PKD Abs to detect PKD constructs. Effect of induced expression of WT (C) and mutant PKD molecules (D) on IgM secretion. Cells were pretreated overnight with 100 µM IPTG to induce expression of the various PKD constructs, and IgM secretion was measured, as in Fig. 1. Results are mean ± SE of replicate cultures, and are representative of two similar experiments.

View larger version (33K): [in this window] [in a new window]   FIGURE 5. Role of the PKD-PH domain in BCR/CD40 synergy. A, Expression of PHD constructs. CH12.LacR cells stably transfected with the various PKD constructs were treated with 100 µM IPTG overnight to induce the expression of the recombinant proteins. Cells were lysed, and immunoprecipitation was performed, as described in Materials and Methods. Immunoprecipitated proteins were separated by SDS-PAGE, and Western blotting was performed with anti-PKD Abs to detect the PKD constructs. B and C, Effect of PH domain mutants on CD40-mediated IgM secretion. Cells were pretreated overnight with 100 µM IPTG to induce expression of the various PKD molecules, and IgM-secreting cells were enumerated, as in Fig. 1. Results are mean ± SE of replicate cultures, and are representative of two similar experiments.

Previously, we demonstrated that BCR signaling is not able to synergize with CD40 molecules that bind TRAF3 in the absence of TRAF2 (30), although BCR can synergize with mutant CD40 molecules that bind neither TRAF2 nor TRAF3 (30). We thus hypothesize that TRAF3 binding to CD40 plays a negative role in BCR/CD40 synergy, and the major role of TRAF2 is to prevent TRAF3 from exerting its negative effects, so TRAF2 is not required for synergy if CD40 is not binding TRAF3. PKD inactivation in CH12.LX cells, either by chemical inhibitors or genetic manipulation, has the same effect on the BCR/CD40 synergy as does CD40 binding of TRAF3 in the absence of TRAF2, suggesting the unexpected, but intriguing possibility that PKD interacts with TRAFs to regulate BCR-CD40 synergy. To address this possibility, we tested whether PKD activation is required for synergy in the absence of TRAF3 binding to CD40. We used an hCD40 mutant (hCD4022) that binds neither TRAF2 nor TRAF3 (30) as well as TRAF3-deficient CH12.LX cells.⁴ If PKD inhibition plays no role in the synergy between BCR and hCD4022, or between BCR and endogenous CD40 in the TRAF3^-/- cells, it would indicate that in the absence of TRAF3, PKD is unnecessary for BCR/CD40 synergy.

This finding would imply that PKD contributes to the synergy by inhibiting TRAF3 from exerting its negative effect. The second possibility is that PKD inhibition leads to abrogation of synergy, and this would suggest that PKD effects on synergy are independent from TRAFs 2 and 3, but act through other molecules downstream of PKD.

As before, treatment of CH12.LX B cells with the PKD inhibitor, Gö6976, abrogated the synergy between BCR and endogenous WT mouse CD40 (mCD40) (which binds TRAF3 and TRAF2). WT hCD40 signals to mouse B cells indistinguishably from endogenous mCD40 (Fig. 6, C and D). However, Gö6976 treatment had no effect on the synergy between BCR and hCD4022, which does not bind TRAF3 or TRAF2 (Fig. 6A). Similar findings were observed using cells that express hCD4022 and the PKD-KD (Fig. 6B). These data support the hypothesis that PKD activation exerts its effects on synergy via the binding of TRAFs to CD40. Whether PKD activation plays an important role in BCR-CD40 synergy in the absence of TRAF3 binding to CD40 was also tested in TRAF3^-/- cells. TRAF3^-/- CH12.LX cells were generated using gene targeting by homologous recombination.⁴ Supporting the findings in Fig. 6, A and B, PKD inactivation either by inhibitors (Fig. 7A) or by expression of inactive PKD (Fig. 7B) did not affect synergy in the TRAF3-deficient B cells. These findings indicate that PKD exerts a novel BCR-mediated effect on TRAF3 that prevents its negative effect on BCR-CD40 synergy.

View larger version (30K): [in this window] [in a new window]   FIGURE 6. Role of TRAFs 2 and 3 in effects of PKD on BCR-CD40 synergy. A, CH12.LX cells expressing hCD4022 were stimulated with 2 µg/ml of mAbs to endogenous mCD40 (1C10) or transfected hCD4022 (G28-5), in the presence and absence of Gö6976 (100 nM), and IgM secretion was measured, as in Fig. 1. B, CH12.LacR cells transfected with PKD-KD and hCD4022 were stimulated as indicated in the presence or absence of 100 µM IPTG, and IgM-secreting cells were enumerated, as in Fig. 1. C, CH12.LX cells transfected with hCD40 were stimulated as indicated, and IgM-secreting cells were enumerated, as in Fig. 1. D, CH12.LacR cells transfected with PKD-KD and hCD40 were stimulated as indicated in the presence or absence of 100 µM IPTG, and IgM-secreting cells were enumerated as in Fig. 1. Results for all panels indicate mean ± SE of replicate cultures, and are representative of two similar experiments.

View larger version (34K): [in this window] [in a new window]   FIGURE 7. PKD inactivation does not abrogate BCR-CD40 synergy in TRAF3-/- cells. A, CH12.LX and CH12.LX-TRAF3-/- cells were stimulated as indicated in the presence and absence of Gö6976 (100 nM), and IgM secretion was measured, as in Fig. 1. B, CH12.LacR and CH12.TRAF3-/-LacR cells transfected with PKD-KD were stimulated as indicated in the presence or absence of 100 µM IPTG, and IgM-secreting cells were enumerated, as in Fig. 1. Results for both panels indicate mean ± SE of replicate cultures, and are representative of two similar experiments.

We have previously shown that the hCD40 mutant T234A, when expressed in B cells, binds TRAF3 normally, but shows reduced binding to TRAF2 (30). This mutant also fails to synergize with BCR signals (30, 40), suggesting that PKD activation must cooperate with TRAF2 to promote synergy; the apparent direct or indirect effects of PKD on TRAF3 are either insufficient or not realized in the absence of TRAF2 binding. To test this hypothesis, we expressed hCD40T234A in CH12.LX cells inducibly expressing PKD-PHD-EE, and asked whether induced expression of the constitutively active PKD could overcome the synergy defect of the hCD40 mutant. As predicted by Fig. 5, induced expression of PKD-PHD-EE substituted for the BCR signal in synergy with the WT endogenous mCD40. However, the kinase activation was insufficient to replace the BCR signal in cooperating with hCD40T234A (Fig. 8). Thus, PKD appears to inactivate a negative effect of TRAF3 on synergy, in a manner dependent upon the binding of TRAF2 to CD40.

View larger version (35K): [in this window] [in a new window]   FIGURE 8. PKD enhancement of CD40 is TRAF2 dependent. CH12.LacR cells transfected with PKD-PHD-EE and hCD40T234A were stimulated as indicated in the presence or absence of 100 µM IPTG, and IgM-secreting cells were enumerated, as in Fig. 1. Results indicate mean ± SE of replicate cultures, and are representative of two similar experiments.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Previous studies have shown that BCR engagement leads to PKD activation in B lymphocytes, and suggested a negative role for PKD in BCR signaling by down-regulating Syk-mediated PLC-2 activation (10). Overexpression studies, using 293 epithelial cells, have linked PKD to several kinases, including extracellular signal-regulated kinase (52) and c-Jun N-terminal kinase (53); however, the physiological relevance of these results to normal PKD levels in lymphocyte signaling is unclear. In the present study, PKD-specific chemical inhibitors as well as genetic experiments showed that PKD activation plays a necessary positive role in the synergy between BCR and CD40. Although PKD inactivation did not block CD40 signaling, it abrogated the ability of the BCR to enhance the CD40 response. Further analysis demonstrated a negative role for the PH domain of PKD in BCR-induced activation. These data extend previous reports of the autoinhibitory role of the PH domain (50, 54) and suggest that BCR-induced PKD activation occurs via relief of this autoinhibition. This relief seems to be necessary and sufficient for PKD to enhance the CD40 response, thus revealing a novel role for PKD in B lymphocyte activation.

To integrate the BCR and CD40 signaling pathways, the possible link between PKD and TRAF molecules was explored. There are several ways that PKD activation could enhance the CD40 response. PKD activation could be responsible for activation of downstream signaling molecules that could in turn cooperate with signals initiated by CD40. An additional intriguing possibility is that PKD links BCR and CD40 pathways by directly affecting CD40-signaling components. Interestingly, we previously showed that the contribution of BCR-induced activation in synergy is TRAF2 dependent, because CD40 mutants that bind TRAF3 in the absence of TRAF2 do not synergize with the BCR, although these mutants stimulate CD40 responses (30). In addition, synergy-defective mutants that bind TRAF3 in the absence of TRAF2 are able to synergize when expressed in TRAF3-deficient cells (Haxhinasto and Bishop, data not shown), pointing to the negative effect of TRAF3 in BCR-CD40 synergy. The findings in Fig. 8 further support a direct link between PKD and TRAF2. The PHD-PKD molecule did not synergize with an hCD40 molecule that does not bind TRAF2, although it synergizes with endogenous WT mCD40, which binds TRAF2.

Of particular interest was the finding that in the absence of TRAF3 binding to CD40, PKD activation was not required for synergy (Figs. 6 and 7), indicating that PKD activation directly or indirectly prevents TRAF3 from inhibiting CD40-BCR synergy. Our data support a model (Fig. 9) in which BCR engagement leads to PKD activation, which in turn prevents TRAF3 from exerting negative effects on BCR-CD40 synergy, in a TRAF2-dependent manner. Our studies support a critical role for PKD-TRAF2-TRAF3 interaction in integration of the signals emanating from the BCR and CD40. PKD activation could lead to modifications of TRAF molecules, such as phosphorylation, that could affect their CD40-induced degradation (55, 56). Additionally, PKD could exert its effects via other molecules, such as Syk, PLC- (10), or Btk (57). These and additional possibilities are under current investigation.

View larger version (29K): [in this window] [in a new window]   FIGURE 9. Potential PKD-TRAF2-TRAF3 interaction in BCR/CD40 synergy. Upon ligation by CD154, CD40 associates with TRAF2 and TRAF3. BCR engagement leads to enhancement of CD40 response in a PKD-dependent manner. We propose that PKD activation positively regulates TRAF2, blocking TRAF3 from exerting its negative effects

	Acknowledgments

 
We thank Dr. Vivek Malhotra (University of California, San Diego, CA) for PKD constructs. We thank Dr. Bruce Hostager for helpful discussion, and Luis Ramirez and Karen Larison for excellent technical assistance.

	Footnotes

 
¹ This work was supported by grants from the National Institutes of Health (AI28847, AI49993) and Veterans Administration Merit Review 383 (to G.A.B.).

² Address correspondence and reprint requests to Dr. Gail A. Bishop, Department of Microbiology, University of Iowa, Iowa City, IA 52242. E-mail address: gail-bishop{at}uiowa.edu

³ Abbreviations used in this paper: BCR, B cell Ag receptor; DAG, diacylglycerol; EE, constitutively active; hCD40, human CD40; IPTG, isopropyl--D-thiogalactopyranoside; KD, kinase dead; mCD40, mouse CD40; PH, pleckstrin homology; PHD, PH domain deleted; PKC, protein kinase C; PKD, protein kinase D; PLC, phospholipase C; TRAF, TNFR-associated factor; WT, wild type.

⁴ P. Xie, B. S. Hostager, and G. A. Bishop. Contrasting roles for TRAF3 in signaling by CD40 and its viral oncogenic mimic, LMP1. Submitted for publication.

Received for publication May 14, 2003. Accepted for publication August 28, 2003.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Benschop, R. J., J. C. Cambier. 1999. B cell development: signal transduction by antigen receptors and their surrogates. Curr. Opin. Immunol. 11:143.[Medline]
2. Kurosaki, T.. 2000. Functional dissection of BCR signaling pathways. Curr. Opin. Immunol. 12:276.[Medline]
3. Justement, L. B.. 2000. Signal transduction via the B-cell antigen receptor: the role of protein tyrosine kinases and protein tyrosine phosphatases. Curr. Top. Microbiol. Immunol. 245:1.
4. Gold, M. R.. 2000. Intermediary signaling effectors coupling the B-cell receptor to the nucleus. Curr. Top. Microbiol. Immunol. 245:77.[Medline]
5. Liu, J. L., T. C. Chiles, R. J. Sen, T. L. Rothstein. 1991. Inducible nuclear expression of NF-B in primary B cells stimulated through the surface Ig receptor. J. Immunol. 146:1685.[Abstract]
6. Xie, H., T. L. Rothstein. 1995. Protein kinase C mediates activation of nuclear cAMP response element-binding protein (CREB) in B lymphocytes stimulated through surface Ig. J. Immunol. 154:1717.[Abstract]
7. Newton, A. C.. 1997. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9:161.[Medline]
8. Van Lint, J., A. Rykx, Y. Maeda, T. Vantus, S. Sturany, V. Malhotra, J. R. Vandenheede, T. Seufferlein. 2002. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol. 12:193.[Medline]
9. Mischak, H., W. Kolch, J. Goodnight, W. F. Davidson, U. Rapp, S. Rose-John, J. F. Mushinski. 1991. Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J. Immunol. 147:3981.[Abstract]
10. Sidorenko, S. P., C. L. Law, S. J. Klaus, K. A. Chandran, M. Takata, T. Kurosaki, E. A. Clark. 1996. Protein kinase Cµ (PKCµ) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. Immunity 5:353.[Medline]
11. Chen, Z. Z., K. M. Coggeshall, J. C. Cambier. 1986. Translocation of protein kinase C during membrane immunoglobulin-mediated transmembrane signaling in B lymphocytes. J. Immunol. 136:2300.[Abstract]
12. Martiny-Baron, G., M. G. Kazanietz, H. Mischak, P. M. Blumberg, G. Kochs, H. Hug, D. Marme, C. Schachtele. 1993. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 268:9194.[Abstract/Free Full Text]
13. Iglesias, T., R. T. Waldron, E. Rozengurt. 1998. Identification of in vivo phosphorylation sites required for protein kinase D activation. J. Biol. Chem. 273:27662.[Abstract/Free Full Text]
14. Waldron, R. T., O. Rey, T. Iglesias, T. Tugal, D. Cantrell, E. Rozengurt. 2001. Activation loop Ser⁷⁴⁴ and Ser⁷⁴⁸ in protein kinase D are transphosphorylated in vivo. J. Biol. Chem. 276:32606.[Abstract/Free Full Text]
15. Waldron, R. T., T. Iglesias, E. Rozengurt. 1999. Phosphorylation-dependent protein kinase D activation. Electrophoresis 20:382.[Medline]
16. Matthews, S. A., T. Iglesias, E. Rozengurt, D. Cantrell. 2000. Spatial and temporal regulation of protein kinase D (PKD). EMBO J. 19:2935.[Medline]
17. Matthews, S. A., E. Rozengurt, D. Cantrell. 2000. Protein kinase D: a selective target for antigen receptors and a downstream target for protein kinase C in lymphocytes. J. Exp. Med. 191:2075.[Abstract/Free Full Text]
18. Parker, D. C.. 1993. T cell-dependent B cell activation. Annu. Rev. Immunol. 11:331.[Medline]
19. Allen, R. C., R. J. Armitage, M. E. Conley, H. Rosenblatt, N. A. Jenkins, N. G. Copeland, M. A. Bedell, S. Edelhoff, C. M. Disteche, D. K. Simoneaux, et al 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990.[Abstract]
20. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, M. Neubauer, et al 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72:291.[Medline]
21. DiSanto, J. P., J. Y. Bonnefoy, J. F. Gauchat, A. Fischer, G. de Saint Basile. 1993. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 361:541.[Medline]
22. Castigli, E., F. W. Alt, L. Davidson, A. Bottaro, E. Mizoguchi, A. K. Bhan, R. S. Geha. 1994. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc. Natl. Acad. Sci. USA 91:12135.[Abstract/Free Full Text]
23. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167.[Medline]
24. Xu, J., T. M. Foy, J. D. Laman, E. A. Elliott, J. J. Dunn, T. J. Waldschmidt, J. Elsemore, R. J. Noelle, R. A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity 1:423.[Medline]
25. Grammer, A. C., P. E. Lipsky. 2000. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv. Immunol. 76:61.[Medline]
26. Bishop, G. A., B. S. Hostager. 2001. Molecular mechanisms of CD40 signaling. Arch. Immunol. Ther. Exp. 49:129.
27. Francis, D. A., J. G. Karras, X. Y. Ke, R. Sen, T. L. Rothstein. 1995. Induction of the transcription factors NF-B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int. Immunol. 7:151.[Abstract/Free Full Text]
28. Sutherland, C. L., A. W. Heath, S. L. Pelech, P. R. Young, M. R. Gold. 1996. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157:3381.[Abstract]
29. Bishop, G. A., W. D. Warren, M. T. Berton. 1995. Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur. J. Immunol. 25:1230.[Medline]
30. Haxhinasto, S. A., B. S. Hostager, G. A. Bishop. 2002. Cutting edge: molecular mechanisms of synergy between CD40 and the B cell antigen receptor: role for TNF receptor-associated factor 2 in receptor interaction. J. Immunol. 169:1145.[Abstract/Free Full Text]
31. Wheeler, K., J. D. Pound, J. Gordon, R. Jefferis. 1993. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur. J. Immunol. 23:1165.[Medline]
32. Baccam, M., G. A. Bishop. 1999. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-B-independent IL-6 production in B cells. Eur. J. Immunol. 29:3855.[Medline]
33. Snapper, C. M., M. R. Kehry, B. E. Castle, J. J. Mond. 1995. Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells: a redefinition of the TI-2 vs T cell-dependent antigen dichotomy. J. Immunol. 154:1177.[Abstract]
34. Huo, L., T. L. Rothstein. 1995. Receptor-specific induction of individual AP-1 components in B lymphocytes. J. Immunol. 154:3300.[Abstract]
35. Li, Y. Y., M. Baccam, S. B. Waters, J. E. Pessin, G. A. Bishop, G. A. Koretzky. 1996. CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J. Immunol. 157:1440.[Abstract]
36. Sakata, N., H. Kawasome, N. Terada, P. Gerwins, G. L. Johnson, E. W. Gelfand. 1999. Differential activation and regulation of mitogen-activated protein kinases through the antigen receptor and CD40 in human B cells. Eur. J. Immunol. 29:2999.[Medline]
37. Mercolino, T. J., L. W. Arnold, G. Haughton. 1986. Phosphatidyl choline is recognized by a series of Ly-1⁺ murine B cell lymphomas specific for erythrocyte membranes. J. Exp. Med. 163:155.[Abstract/Free Full Text]
38. Bishop, G. A., G. Haughton. 1986. Induced differentiation of a transformed clone of Ly-1⁺ B cells by clonal T cells and antigen. Proc. Natl. Acad. Sci. USA 83:7410.[Abstract/Free Full Text]
39. Hostager, B. S., G. A. Bishop. 1999. Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J. Immunol. 162:6307.[Abstract/Free Full Text]
40. Hostager, B. S., Y. Hsing, D. E. Harms, G. A. Bishop. 1996. Different CD40-mediated signaling events require distinct CD40 structural features. J. Immunol. 157:1047.[Abstract]
41. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51.[Medline]
42. Bishop, G. A.. 1991. Requirements of class II-mediated B cell differentiation for class II cross-linking and cyclic AMP. J. Immunol. 147:1107.[Abstract]
43. Armitage, R. J., B. M. Macduff, M. K. Spriggs, W. C. Fanslow. 1993. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J. Immunol. 150:3671.[Abstract]
44. Boussiotis, V. A., L. M. Nadler, J. L. Strominger, A. E. Goldfeld. 1994. Tumor necrosis factor is an autocrine growth factor for normal human B cells. Proc. Natl. Acad. Sci. USA 91:7007.[Abstract/Free Full Text]
45. Hostager, B. S., G. A. Bishop. 2002. Role of TNF receptor-associated factor 2 in the activation of IgM secretion by CD40 and CD120b. J. Immunol. 168:3318.[Abstract/Free Full Text]
46. Qatsha, K. A., C. Rudolph, D. Marme, C. Schachtele, W. S. May. 1993. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl. Acad. Sci. USA 90:4674.[Abstract/Free Full Text]
47. Gschwendt, M., S. Dieterich, J. Rennecke, W. Kittstein, H. J. Mueller, F. J. Johannes. 1996. Inhibition of protein kinase Cµ by various inhibitors: differentiation from protein kinase C isoenzymes. FEBS Lett. 392:77.[Medline]
48. Zugaza, J. L., J. Sinnett-Smith, J. Van Lint, E. Rozengurt. 1996. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J. 15:6220.[Medline]
49. Liljedahl, M., Y. Maeda, A. Colanzi, I. Ayala, J. Van Lint, V. Malhotra. 2001. Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network. Cell 104:409.[Medline]
50. Iglesias, T., E. Rozengurt. 1998. Protein kinase D activation by mutations within its pleckstrin homology domain. J. Biol. Chem. 273:410.[Abstract/Free Full Text]
51. Rey, O., J. Sinnett-Smith, E. Zhukova, E. Rozengurt. 2001. Regulated nucleocytoplasmic transport of protein kinase D in response to G protein-coupled receptor activation. J. Biol. Chem. 276:49228.[Abstract/Free Full Text]
52. Hausser, A., P. Storz, S. Hubner, I. Braendlin, M. Martinez-Moya, G. Link, F. J. Johannes. 2001. Protein kinase Cµ selectively activates the mitogen-activated protein kinase (MAPK) p42 pathway. FEBS Lett. 492:39.[Medline]
53. Brandlin, I., S. Hubner, T. Eiseler, M. Martinez-Moya, A. Horschinek, A. Hausser, G. Link, S. Rupp, P. Storz, K. Pfizenmaier, F. J. Johannes. 2002. Protein kinase C (PKC)-mediated PKCµ activation modulates ERK and JNK signal pathways. J. Biol. Chem. 277:6490.[Abstract/Free Full Text]
54. Waldron, R. T., E. Rozengurt. 2003. Protein kinase C phosphorylates protein kinase D activation loop Ser⁷⁴⁴ and Ser⁷⁴⁸ and releases autoinhibition by the pleckstrin homology domain. J. Biol. Chem. 278:154.[Abstract/Free Full Text]
55. Brown, K. D., B. S. Hostager, G. A. Bishop. 2001. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J. Exp. Med. 193:943.[Abstract/Free Full Text]
56. Brown, K. D., B. S. Hostager, G. A. Bishop. 2002. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277:19433.[Abstract/Free Full Text]
57. Johannes, F. J., A. Hausser, P. Storz, L. Truckenmuller, G. Link, T. Kawakami, K. Pfizenmaier. 1999. Bruton’s tyrosine kinase (Btk) associates with protein kinase Cµ. FEBS Lett. 461:68.[Medline]
58. Hostager, B. S., S. A. Haxhinasto, S. L. Rowland, and G. A. Bishop. TRAF2-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J. Biol. Chem. In press.

This article has been cited by other articles:

				I. Guasparri, D. Bubman, and E. Cesarman EBV LMP2A affects LMP1-mediated NF-{kappa}B signaling and survival of lymphoma cells by regulating TRAF2 expression Blood, April 1, 2008; 111(7): 3813 - 3820. [Abstract] [Full Text] [PDF]

				S. M. Ivison, N. R. Graham, C. Q. Bernales, A. Kifayet, N. Ng, L. A. Shobab, and T. S. Steiner Protein Kinase D Interaction with TLR5 Is Required for Inflammatory Signaling in Response to Bacterial Flagellin J. Immunol., May 1, 2007; 178(9): 5735 - 5743. [Abstract] [Full Text] [PDF]

				M. E. Munroe and G. A. Bishop A Costimulatory Function for T Cell CD40 J. Immunol., January 15, 2007; 178(2): 671 - 682. [Abstract] [Full Text] [PDF]

				A. Irie, K. Harada, H. Tsukamoto, J.-R. Kim, N. Araki, and Y. Nishimura Protein kinase D2 contributes to either IL-2 promoter regulation or induction of cell death upon TCR stimulation depending on its activity in Jurkat cells Int. Immunol., December 1, 2006; 18(12): 1737 - 1747. [Abstract] [Full Text] [PDF]

				P. Xie, B. S. Hostager, M. E. Munroe, C. R. Moore, and G. A. Bishop Cooperation between TNF Receptor-Associated Factors 1 and 2 in CD40 Signaling J. Immunol., May 1, 2006; 176(9): 5388 - 5400. [Abstract] [Full Text] [PDF]

				S. Wu, P. Xie, K. Welsh, C. Li, C.-Z. Ni, X. Zhu, J. C. Reed, A. C. Satterthwait, G. A. Bishop, and K. R. Ely LMP1 Protein from the Epstein-Barr Virus Is a Structural CD40 Decoy in B Lymphocytes for Binding to TRAF3 J. Biol. Chem., September 30, 2005; 280(39): 33620 - 33626. [Abstract] [Full Text] [PDF]

				C. R. Moore and G. A. Bishop Differential Regulation of CD40-Mediated TNF Receptor-Associated Factor Degradation in B Lymphocytes J. Immunol., September 15, 2005; 175(6): 3780 - 3789. [Abstract] [Full Text] [PDF]

				S. A. Haxhinasto and G. A. Bishop Synergistic B Cell Activation by CD40 and the B Cell Antigen Receptor: ROLE OF B LYMPHOCYTE ANTIGEN RECEPTOR-MEDIATED KINASE ACTIVATION AND TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR REGULATION J. Biol. Chem., January 23, 2004; 279(4): 2575 - 2582. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haxhinasto, S. A. Articles by Bishop, G. A. Search for Related Content PubMed PubMed Citation Articles by Haxhinasto, S. A. Articles by Bishop, G. A.